Plecanatide - Synergy Pharmaceuticals

Drug Profile

Plecanatide - Synergy Pharmaceuticals

Alternative Names: GCRA; Guanilib; SP-304; TRULANCE

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Callisto Pharmaceuticals
  • Developer Synergy Pharmaceuticals Inc
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Guanylate cyclase C agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome
  • Discontinued Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 07 Aug 2018 Plecanatide licensed to Shandong Luoxin in China, Macau and Hong-Kong
  • 10 Jul 2018 Efficacy and adverse data from a phase III trial in Constipation-predominant irritable bowel syndrome presented at the Digestive Disease Week 2018
  • 30 Jun 2018 Phase-II clinical trials in Irritable bowel syndrome (In adolescents, In children) in USA (PO) (NCT03596905)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top